# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee

> **NCT02126826** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 58 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** BI 1026706
- **DRUG:** Placebo to BI 1026706

## Key facts

- **NCT ID:** NCT02126826
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-28
- **Primary completion:** 2014-10-01
- **Final completion:** 2014-10-21
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02126826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02126826, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02126826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*